die('
Site is under construction
Dear site users
Site is under construction.
The site will be ready in less than 24 hours.
We are sorry for the inconvenience.
www.yektaweb.com
');
Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61882/rbmb
en
jalali
1399
2
1
gregorian
2020
5
1
9
1
online
1
fulltext
en
Decreased Threshold of Fasting Serum Glucose for Cardiovascular Events: MASHAD Cohort Study
بیوشیمی
Biochemistry
مقالات اصلی
Original Article
<div style="text-align: justify;"><em><strong>Background:</strong> </em>Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, and specifically in Iran. Generally, diabetes mellitus is the result of impaired glucose tolerance which together with dyslipidemia are considered as important risk factors of CVD. The aim of this study was to determine the relationship between fasting serum glucose (FSG), lipid profile and CVD endpoints, and to establish an optimal FSG cut-off in the MASHAD cohort study after nearly 6 years of follow-up.<br>
<em><strong>Methods:</strong></em> All the participants of MASHAD study were followed up for 6 years to determine their cardiovascular status. FSG, fasting lipids, and physical examinations were all recorded. To identify the optimal cut- off point of FSG, we carried out receiver operating curve (ROC) analysis<br>
<strong><em>Results:</em></strong> We determined MASHAD cutoff point of blood glucose as 90 mg/dl predicting the CVD outcome. The sensitivity and specificity of the FSG criterion were 54.34% and 71.68%, respectively. The AUC was 0.665 (95% CI 0.656-0.675, P< 0.0001). The adjusted hazard ratio show that FSG is associated with 2.34 increase in CVD risk using MASHAD cutoff point (HR 2.34, 95% 1.73–3.17, P< 0.001).<br>
<strong><em>Conclusions:</em></strong> These findings suggest that not only FSG and lipid profile are related to CVD outcome in the MASHAD study, but also elevated fasting glucose levels is strongly associated with cardiovascular events in this population. Besides, the fasting glucose at a threshold of 90 mg/dl can be used for screening cardiovascular events among the Iranian population.</div>
Fasting Serum Glucose, Lipid profile, Cardiovascular disease (CVD), MASHAD cohort study.
64
70
http://rbmb.net/browse.php?a_code=A-10-266-2&slc_lang=en&sid=1
Fatemeh
Sadabadi
Sadabadif2@mums.ac.ir
100319475328460017512
100319475328460017512
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Aida
Gholoobi
Gholoubiad@mums.ac.ir
100319475328460017513
100319475328460017513
No
Medical Genetics Research Centre, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
Alireza
Heidari-Bakavol
100319475328460017514
100319475328460017514
No
Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohsen
Mouhebati
100319475328460017515
100319475328460017515
No
Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ali
Javandoost
100319475328460017516
100319475328460017516
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra
Asadi
100319475328460017517
100319475328460017517
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam
Saberi-Karimian
100319475328460017518
100319475328460017518
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Susan
Darroudi
100319475328460017519
100319475328460017519
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Sadegh
Khorrami Mohebbseraj
100319475328460017520
100319475328460017520
No
Department of Medical Genetic and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Farzad
Rahmani
100319475328460017521
100319475328460017521
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Najmeh
Malekzadeh Gonabadi
100319475328460017522
100319475328460017522
No
Department of genetic, School of science, Sistan and Baluchestan University, Zahedan, Iran.
Fatemehalsadat
Jafari Sheshtamad
100319475328460017523
100319475328460017523
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Sara
Samadi
100319475328460017524
100319475328460017524
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Afsane
Bahrami
100319475328460017525
100319475328460017525
No
Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Gordon
Ferns
100319475328460017526
100319475328460017526
No
Department of Medical Education, Brighton & Sussex Medical School, Brighton, BN1 9PH, UK
Majid
Ghayour-Mobarhan
100319475328460017527
100319475328460017527
No
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. & International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Habibollah
Esmaeili
100319475328460017528
100319475328460017528
Yes
Department of Biostatistics & Epidemiology, School of Health, Management & Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.